Kyle Registre's childhood dream of becoming a pilot can finally come true now that he says he's been cured of sickle cell complications.

On Tuesday, the Buffalo community came together to spread awareness about sickle cell disease during Black History Month.

Vertex has entered a reimbursement agreement with NHS England enabling eligible SCD patients to access Casgevy in the public ...

For Vertex these days, it’s all about the launches of three new products—sickle cell disease gene therapy Casgevy, the ...

Stuart Arbuckle, who’s been with Vertex since 2012, plans to retire from his role in July. His departure comes as Vertex ...

Reshma Kewalramani; President, Chief Executive Officer, Director; Vertex Pharmaceuticals Inc Stuart Arbuckle; Chief Operating Officer, Executive Vice President; Vertex Pharmaceuticals Inc Charles ...

Q4 2024 Earnings Call Transcript February 10, 2025 Vertex Pharmaceuticals Incorporated misses on earnings expectations. Reported EPS is $3.98 EPS, expectations were $4.02. Operator: Good day, and ...

Vertex Pharmaceuticals Inc. will soon lose a member of its leadership team that helped the company achieve major revenue ...

The cystic fibrosis treatment leader exceeded revenue expectations, but missed slightly on earnings per share.

To illustrate that point, let's discuss two stocks in the biotech industry that have moved in opposite directions so far this ...

Fulcrum Therapeutics' promising treatment for Sickle Cell Disease and their strong financial position, despite setbacks.

With the addition of Casgevy, Children’s Hospital Los Angeles now offers two gene therapies for sickle cell, the first being Lyfgenia.